07:29 AM EDT, 08/11/2025 (MT Newswires) -- Immunovant ( IMVT ) reported a fiscal Q1 net loss Monday of $0.71 per diluted share, wider than the net loss of $0.60 a year earlier.

Analysts polled by FactSet expected a loss of $0.68.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the company said it had $598.9 million in cash and or cash equivalents on hand, which will likely finance operations through its Graves' disease trial readout anticipated in 2027.